Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision on the page updated from v3.5.3 to v3.5.4, signaling a small patch or administrative update to the page metadata. No changes to the study content or user-facing information are indicated.
    Difference
    0.1%
    Check dated 2026-05-17T09:11:02.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Melanoma is added as a study topic and a Related topics section includes MedlinePlus Genetics, broadening navigational connections to related consumer health resources. These additions also connect the study to genetics information relevant to the condition.
    Difference
    0.2%
    Check dated 2026-05-10T08:54:21.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page header/footer was updated to a new site software revision version (v3.5.3 instead of v3.5.2) without any accompanying changes to the study record content.
    Difference
    0.1%
    Check dated 2026-04-25T18:31:54.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2. Melanoma and the related topic MedlinePlus Genetics, along with the Revision: v3.5.0 reference, were removed.
    Difference
    0.2%
    Check dated 2026-04-18T13:21:07.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Added Melanoma as a topic and MedlinePlus Genetics under related topics; no deletions were made.
    Difference
    0.2%
    Check dated 2026-04-11T10:29:03.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The Melanoma topic and the MedlinePlus Genetics link were removed from the Related Topics section. This reduces quick access to disease context and related educational resources.
    Difference
    0.2%
    Check dated 2026-04-04T05:25:10.000Z thumbnail image

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.